However, when two or more foci of prostate cancer separated by intervening benign tissue are present in a single core biopsy, there is currently no consensus dictating the optimal method to report ...

MINNEAPOLIS, March 7, 2017 /PRNewswire/ -- Bio-Techne has entered into an exclusive license agreement with Multiclonal Therapeutics (MCT) to commercialize reagents and media systems in the research ...